Inicio › Cáncer de ovario › Luisiana › New Orleans
Ensayos clínicos de Cáncer de ovario en New Orleans, LA
12 estudios para Cáncer de ovario buscan participantes en centros de New Orleans y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
ReclutandoFase 3
- Louisiana State University HSC - NO Cancer Center, New Orleans
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ReclutandoFase 2/3
- University Medical Center New Orleans, New Orleans
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutandoFase 2
- Ochsner Medical Center Jefferson, New Orleans
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
ReclutandoEstudio observacional
- Ochsner Clinic Foundation, New Orleans
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
ReclutandoFase 2
- University Medical Center New Orleans /ID# 274755, New Orleans
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
ReclutandoFase 3
- Ochsner Clinic Foundation, New Orleans
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
ReclutandoEstudio observacional
- Tulane Cancer Center, New Orleans
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Reclutando
- Louisiana State University Health Science Center, New Orleans
- University Medical Center New Orleans, New Orleans
- West Jefferson Medical Center, Marrero · A 4 mi de distancia
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
ReclutandoFase 3
- University Medical Center New Orleans, New Orleans
- Ochsner Baptist Medical Center, New Orleans
- Ochsner Medical Center Jefferson, New Orleans
- y 1 más
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Louisiana State University Health Sciences Center, New Orleans
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
ReclutandoFase 3
- LSU Health New Orleans, New Orleans
- University Medical Center New Orleans, New Orleans
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, New Orleans
Más información sobre Cáncer de ovario en MedlinePlus
Ensayos de Cáncer de ovario en otras ciudades
- Houston, TX89 estudios
- New York City, NY69 estudios
- Boston, MA61 estudios
- Los Angeles, CA50 estudios
- Nashville, TN49 estudios
- Arlington, VA46 estudios
- Philadelphia, PA44 estudios
- Columbus, OH39 estudios
- St. Louis, MO38 estudios
- Chicago, IL36 estudios
- San Antonio, TX31 estudios
- Cleveland, OH30 estudios
Otros estudios en New Orleans
- Cáncer (todos los tipos)12 estudios
- Cáncer de seno11 estudios
- Cáncer de próstata10 estudios
- Cáncer de endometrio9 estudios
- Cáncer metastásico9 estudios
- Cáncer de pulmón9 estudios
- Cáncer de pulmón de células no pequeñas9 estudios
- Enfermedad cardiovascular9 estudios
- Obesidad8 estudios
- Esteatosis hepática8 estudios
- Cáncer del colon y del recto8 estudios
- Fibrilación auricular8 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.